cherry (@chertrades) profile picture
Joined July 2020
Photo by cherry (@chertrades)
Please don’t ever cover, dumbasses
The Oppenheimer report today by Suraj Kalia “refuting” our $TMDX TransMedics report is getting some airtime on this platform. Kalia has an abysmal track record defending medtech scams. Our thoughts: 1. Kalia is one of two medtech analysts, along with Bill Plovanic at Canaccord, who cover $TMDX who also covered $NVRO, our first short report under Scorpion in 2021. All you need to know is that Nevro is -98% since we published. Plovanic hiked his price target to $225 after our report. The stock is now $5. We reached out to Kalia back then and he replied that he won’t talk to a short-seller. 2. Kalia’s report today says “over the past 3 weeks we have conducted numerous calls with surgeons, OPO’s, and industry contacts.” How many calls? His 5-page note has only a half-page summary, no other detail, and 4 pages of disclosures. One would expect at least some details after all that value-added research. 3. The lack of detail is particularly striking given the strength of his assertions, such as where he states that “some sites flat out denied statements attributed to them.” Which sites? If you don’t want to state the source, why not at least mention the nature of the statements? 4. His report continues that “industry sources tell us that some OPO’s cited in the report complained that their comments were taken out of context in the short report.” What type of industry source and which OPO’’s did they speak to?
47
$INOD I'm sorry you said your target was $5, right? Did you forget a 5? Cause it's $55 now. Hope you blew up for trying to spread misinformation to benefit your short and trying to scam shareholders out of solid growth anyone else could see from miles away. I should thank you tho
Can $INOD be more clear @innodata; is this a target subpoena? $INOD receives a grand jury subpoena the day before 2Q drops and we're just now hearing about it a Q later...nothing to see here
264
$inod LOL you're so f*cked just cover man, jesus christ. You're far from hindenberg and this isn't SMCI. Stocks now up what, 300% since your 3rd grade level report? So obvious how underwater you are its up 50% today and you release this. No sympathy man.
$INOD Regulatory Update per the latest Q: 1. Letter received from the SEC in March requesting $INOD preserve certain documents 2. DOJ grand jury subpoena received in August 3. SEC subpoena received in September
1
159
$INOD LOOOOOOOOOOOOOOSERRRRRRR
Replying to @InvestorJoe777
How's ur squeeze working out dipshit. Anonymous tough guy, ur all the same loser.
1
222
$INOD has more to squeeze - ultimately a lot more, but more today too and its already up 45%
87
$8.80 high after ER- up 30% from close on strong earnings growth, new contracts, added spend on existing contracts, raised guidance, and increased cash on balance sheet by almost 40%. If you’re as dumb as your report you didn’t cover yet so have fun with that.
Replying to @InvestorJoe777
Oh, honey, shhhhhhh, it will all be over soon. I'm afraid the ten bucks you've invested in $INOD will only be worth five very soon, and then two.
1
91